Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
The defining idea of 2025 was execution at scale—more patients pulled into…
ESMO Immuno-Oncology 2025 Preview: Key Highlights to Watch
ESMO Immuno-Oncology 2025 at a glance Get ready for ESMO Immuno-Oncology…
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration Professional…
Lucid Diligence Brief: Sprint Bioscience sells TREX1 program to Gilead
Lucid Diligence Brief: Sprint Bioscience sells TREX1 program to Gilead…
Lucid Diligence Brief: Vaximm VXM01 License Term Sheet with BCM Europe
Lucid Diligence Brief: Vaximm VXM01 License Term Sheet with BCM Europe…
Lucid Diligence Brief: ModeX Therapeutics and Regeneron collaboration
Lucid Diligence Brief: ModeX Therapeutics and Regeneron collaboration…
Lucid Diligence Brief: Takeda and Innovent global oncology partnership
Lucid Diligence Brief: Takeda and Innovent global oncology partnership…
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics Professional…
Oncology Weekly News - September 22nd 2025
Oncology Update: RGT-61159 Orphan Drug, CRB-701 Fast Track, PDS0101 Survival…